Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study

Thyroid

Volumn 27, Issue 7, 2017, Pages 894-901

  Yamauchi, Ichiro ^a   Sakane, Yoriko ^a,b   Fukuda, Yorihide ^a   Fujii, Toshihito ^a   Taura, Daisuke ^a   Hirata, Masakazu ^a   Hirota, Keisho ^a   Ueda, Yohei ^a   Kanai, Yugo ^a   Yamashita, Yui ^a   Kondo, Eri ^a   Sone, Masakatsu ^a   Yasoda, Akihiro ^a   Inagaki, Nobuya ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

immune checkpoint inhibitor; nivolumab; painless thyroiditis; PD 1; thyrotoxicosis

Indexed keywords

BETA INTERFERON; CAPECITABINE; CARBOPLATIN; DACARBAZINE; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GLUCOCORTICOID; LEVOTHYROXINE; LIOTHYRONINE; MESSENGER RNA; NEDAPLATIN; NIMUSTINE; NIVOLUMAB; PACLITAXEL; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; THYROTROPIN; THYROXINE; UFT; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HASHIMOTO DISEASE; HELA CELL LINE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; LUNG CANCER; MALE; MCF-7 CELL LINE; MEDICAL RECORD REVIEW; MELANOMA; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID GLAND TISSUE; THYROIDITIS; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; WESTERN BLOTTING; BLOOD; BREAST TUMOR; CASE REPORT; CHEMICALLY INDUCED; LUNG TUMOR; SKIN TUMOR; SYMPTOM ASSESSMENT;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SYMPTOM ASSESSMENT; THYROIDITIS; THYROTOXICOSIS; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 85022190469     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2016.0562     Document Type: Article

References (38)

1. Leach DR, Krummel MF, Allison JP 1996 Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736
2. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL 2010 Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175
3. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, Strome SE, Pease LR, Chen L 2002 Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 109:651-659
4. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T, Sakaguchi S 2005 Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 202:885-891
5. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM 2010 Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207:2175-2186
6. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC 2010 Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207:2187-2194
7. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA 2012 Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72:917-927
8. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F 2013 Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98:1361-1375
9. Abdel-Wahab N, Shah M, Suarez-Almazor ME 2016 Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One 11:e0160221
10. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ 2010 Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
11. Squibb B-M Yervoy Tentekijochu Fukusayoukensu-ichiran (August 31 2015 to February 29 2016) [in Japanese]. Available at: https://file.bmshealthcare.jp/yervoy/pdf/side- effect0229-2.pdf (accessed August 31, 2016)
12. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T 2000 Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-1034
13. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ 2001 PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261-268
14. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P 2015 PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311-319
15. Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML 2016 Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856-1867
16. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Jr., Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J 2015 Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol 16:375-384
17. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR, Jr., Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR 2015 Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639
18. Co. OP 2016 Opdivo Tentekijochu Fukusayoukensuichiran ( July 4 2014 to August 15 2016) [in Japanese]. Available at: www.opdivo.jp/contents/pdf/open/side-effect .pdf (accessed August 31, 2016)
19. Orlov S, Salari F, Kashat L, Walfish PG 2015 Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab 100:1738-1741
20. Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, Bravenboer B 2016 Incidence of thyroidrelated adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 101:4431-4439
21. Verma I, Modi A, Tripathi H, Agrawal A 2016 Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung. BMJ Case Rep 2016:10.1136/bcr-2015-213692
22. McMillen B, Dhillon MS, Yong-Yow S 2016A rare case of thyroid storm. BMJ Case Rep 2016:10.1136/bcr-2016-214603
23. Tanaka R, Fujisawa Y, Maruyama H, Nakamura Y, Yoshino K, Ohtsuka M, Fujimoto M 2016 Nivolumabinduced thyroid dysfunction. Jpn J Clin Oncol 46:575-579
24. French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC Jr, Klopper JP, Haugen BR 2012 Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab 97: E934-943
25. Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Mateescu V, Sams SB, Davies KD, Raeburn CD, McIntyre RC Jr, Haugen BR, French JD 2016 Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 101:2863-2873
26. Enomoto T, Sugawa H, Inoue D, Miyamoto M, Kosugi S, Takahashi T, Kitamura N, Yamamoto I, Konishi J, Mori T, et al. 1990 Establishment of a human undifferentiated thyroid cancer cell line producing several growth factors and cytokines. Cancer 65:1971-1979
27. Chen Y, Wang Q, Shi B, Xu P, Hu Z, Bai L, Zhang X 2011 Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine 56:231-238
28. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T 2013A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14:1212-1218
29. Dong H, Zhu G, Tamada K, Chen L 1999 B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5:1365-1369
30. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L 2002 Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793-800
31. Severson JJ, Serracino HS, Mateescu V, Raeburn CD, McIntyre RC Jr, Sams SB, Haugen BR, French JD 2015 PD-1+Tim-3+ CD8+ T lymphocytes display varied degrees of functional exhaustion in patients with regionally metastatic differentiated thyroid cancer. Cancer Immunol Res 3:620-630
32. Hayashi M, Kouki T, Takasu N, Sunagawa S, Komiya I 2008 Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients. Eur J Endocrinol 158: 817-822
33. Inoue H, Park JH, Kiyotani K, Zewde M, Miyashita A, Jinnin M, Kiniwa Y, Okuyama R, Tanaka R, Fujisawa Y, Kato H, Morita A, Asai J, Katoh N, Yokota K, Akiyama M, Ihn H, Fukushima S, Nakamura Y 2016 Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology 5:e1204507
34. Sarvghadi F, Hedayati M, Mehrabi Y, Azizi F 2005 Follow up of patients with postpartum thyroiditis: a populationbased study. Endocrine 27:279-282
35. Stagnaro-Green A, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Negro R 2011 High rate of persistent hypothyroidism in a large-scale prospective study of postpartum thyroiditis in southern Italy. J Clin Endocrinol Metab 96:652-657
36. Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC 2015 Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 38:e55-57
37. Okano Y, Satoh T, Horiguchi K, Toyoda M, Osaki A, Matsumoto S, Tomaru T, Nakajima Y, Ishii S, Ozawa A, Shibusawa N, Shimada T, Higuchi T, Chikamatsu K, Yamada M 2016 Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J 63:905-912
38. Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Hidaka T, Haga T, Hashimoto A, Morimoto R, Aiba S 2017 Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient. J Dermatol 44:e13-14